MST1R Antibody

1. the cis-regulatory landscape that determines alternative splicing of exon 11 in the proto-oncogene MST1R (RON), was examined. PMID: 30120239
2. this study demonstrates the functional significance of RON during prostate cancer progression and provides a strong rationale for targeting RON signaling in prostate cancer as a means to limit resistance to androgen deprivation therapy. PMID: 30121008
3. Study conclude that the splice variants of RON lacking exon 11 and exons 11-13 were detected in several lung cancer cell lines. Novel variant formed by skipping exons 11-13, the sequence of which code for transmembrane region, is predicted to code for a truncated isoform that may be secreted out. PMID: 30223007
4. RONDelta165E2 variant promoted tumor progression while activating the PI3K/AKT pathway via PTEN phosphorylation in colorectal carcinoma. PMID: 28388571
5. These findings indicate that RON and c-Met facilitate metastasis through ERK1/2 signaling and that targeting RON and c-Met with foretinib may be an attractive therapeutic option for suppressing Prostate cancer metastasis PMID: 28440432
6. Forkhead box C1 protein (FOXC1) promotes melanoma cell function by regulating macrophage stimulating 1 receptor (MST1R) and activating MST1R/PI3K/AKT pathway. PMID: 27533251
7. RON has a role in cancer-induced bone destruction and osteoporosis PMID: 28123075
8. RON isoforms may comprise half of total RON transcript in human pancreatic cancer and their expression is regulated at least in part by promoter hypermethylation. PMID: 27323855
9. High RON expression is associated with castration resistant prostate cancer. PMID: 26872377
10. hnRNP A1 directly binds to the 5' untranslated region of the RON mRNA and activates its translation through G-quadruplex RNA secondary structures PMID: 26930004
11. Findings indicate a role of the RON tyrosine kinase receptor in pancreatic cancer and suggest RON as a potential therapeutic target. PMID: 26477314
12. High expression of RON is associated with drug resistance in bladder cancer. PMID: 28075465
13. complete loss of one or both MET and RON, as well as their overexpression, is a poor prognostic factor in patients with extrahepatic cholangiocarcinoma, probably due to the high rate of lymph-node metastasis PMID: 27919987
14. Study identified four novel uniquely spliced RON transcripts in small cell lung carcinoma (SCLC) and Non-SCLC cell lines. PMID: 26775595
15. the MST1R variant c.G917A:p.R306H is highly associated with nasopharyngeal carcinoma (odds ratio of 9.0). PMID: 26951679
16. Results show that under hypoxia, nuclear RON activates non-homologous end joining DNA repair by interacting with Ku70 and DNA-PKcs and confers chemoresistance. PMID: 26772202
17. Aberrant glycosylation of the RON receptor was shown as an alternative mechanism of oncogenic activation. PMID: 26721331
18. Data demonstrated upregulated RON isoform expression and significant changes in splicing factor expression in primary ovarian cancer suggesting a regulatory interplay of splicing factor and RON alternative splicing pattern in ovarian cancer. PMID: 25997828
19. Activation of RON as an alternate mechanism in the development of CRPC. PMID: 26152593
20. the prognostic significance of MET is limited in early stage disease. MET+/RON+ patients had higher overall recurrence rates than those with the other expression patterns PMID: 25874493
21. RON expression in endometrial adenocarcinoma was significantly higher than that in normal endometrial tissues. PMID: 26189249
22. Studies demonstrate that DEK overexpression, due in part to Ron receptor activation, drives breast cancer progression through the induction of Wnt/beta-catenin signaling. PMID: 24954505
23. approach identified 18 kinase and kinase-related genes whose overexpression can substitute for EGFR in EGFR-dependent PC9 cells, and these genes include seven of nine Src family kinase genes, FGFR1, FGFR2, ITK, NTRK1, NTRK2, MOS, MST1R, and RAF1. PMID: 25512530
24. SRSF2 promotes exon 11 inclusion of Ron proto-oncogene through targeting exon 11. PMID: 25220236
25. Results pointed to a novel function for RON as a transcriptional regulator that promotes the survival of cancer cells subjected to hypoxia. PMID: 24903148
26. Data shows that MET and RON are regulated by PAX8 in non-small cell lung cancer. PMID: 24628993
27. Stusies indicate that RON receptor tyrosine kinase is overexpressed and activated in pancreatic tumor specimens. PMID: 24518495
28. RON expression was dominantly observed in laryngeal SCC tissues relative to adjacent normal mucosa. Knockdown of RON resulted in significantly reduced cell invasion and cell migration in human laryngeal SCC cells. PMID: 24287326
29. RON promotes breast cancer metastasis through altered DNA methylation. PMID: 24388747
30. Through double-base and single-base substitution analysis of the 2-nt RNA, this study demonstrated that the GA, CC, UG and AC dinucleotides on exon 11, in addition to the wild-type AG sequence, function as enhancers for exon 11 inclusion of the Ron pre-mRNA. PMID: 24189591
31. intron retention in the RON gene was investigated. PMID: 24155930
32. findings identify the pathway of Ron-c-Abl-PCNA as a mechanism of oncogene-induced cell proliferation, with potentially important implications for development of combination therapy of breast cancer PMID: 23542172
33. Suggest that MET and MST1R are independent prognostic factors in classical classical Hodgkin's lymphoma, and may allow the identification of a subgroup of cHL patients who require more intensive therapy. PMID: 23558571
34. Data suggest that oncogenic RON160 is frequently expressed in primary invasive ductal, lobular, and lymph node-involved breast cancer tissues; RON160 overexpression is predominantly observed in invasive ductal and lymph node-involved cases. PMID: 23597200
35. The MET(-) RON(-) phenotype retained its prognostic impact after subgroup analysis. PMID: 23745832
36. Demonstrate of the important role of RON in mediating lapatinib resistance in breast cancer cells. PMID: 23811285
37. the function of RON in tumors may be multidimensional, not just as a tumor suppressor or oncogene. PMID: 23483216
38. RON may influence carcinogenesis in a number of systemic malignancies. PMID: 23294341
39. Ron synergises with EGFR to confer certain adverse features in head and neck squamous cell carcinomas. PMID: 23799848
40. RON expression is not associated with prognosis or therapeutic responsiveness in resected pancreatic cancer. PMID: 22958871
41. results suggest cytoplasmic phosphorylated RON is a potential marker for poor prognosis in Esophageal squamous cell carcinomapatients. PMID: 22086736
42. study presents two novel splicing variants of RON in the partial splicing events that involve exons 5 and 6; the difference of these two isoforms is the inclusion or skipping of intron 6 PMID: 22993024
43. High RON expression is associated with acute myeloid leukemia. PMID: 22902361
44. These results suggest an important role of RON in the tumorigenesis and metastasis of nasopharyngeal carcinoma. PMID: 22974584
45. Knockdown of RON inhibited invasive growth & the activation of oncogenic signaling pathways including Akt, MAPK and beta-catenin. RON up-regulation was associated with tumor size, lymphatic metastasis, invasiveness, tumor stage and poor survival. PMID: 23235762
46. A new splice variant of RON suggests a novel role for the RON receptor in the progression of metastasis in colorectal cancer. PMID: 22975341
47. the structure of RON Sema-PSI domains at 1.85 A resolution PMID: 22848655
48. High RON expression is associated with small and non-small cell lung cancers. PMID: 22585712
49. tumor promoter induces RON expression via Egr-1, which, in turn, stimulates cell invasiveness in AGS cells PMID: 22095683
50. Elevated RON expression may contribute to the occurrence, progression and metastasis of non-small cell lung cancer(NSCLC), inferring that it could be useful as a new prognostic indicator for patients with NSCLC. PMID: 22613539

显示更多

收起更多

HGNC: 7381

OMIM: 255995

KEGG: hsa:4486

STRING: 9606.ENSP00000296474

UniGene: Hs.517973